CL2014000432A1 - Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica. - Google Patents
Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica.Info
- Publication number
- CL2014000432A1 CL2014000432A1 CL2014000432A CL2014000432A CL2014000432A1 CL 2014000432 A1 CL2014000432 A1 CL 2014000432A1 CL 2014000432 A CL2014000432 A CL 2014000432A CL 2014000432 A CL2014000432 A CL 2014000432A CL 2014000432 A1 CL2014000432 A1 CL 2014000432A1
- Authority
- CL
- Chile
- Prior art keywords
- bacteriochlorophyll
- sclera
- chlorophyll
- cornea
- thinning
- Prior art date
Links
- 108010003118 Bacteriochlorophylls Proteins 0.000 title 1
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 title 1
- 229930002875 chlorophyll Natural products 0.000 title 1
- 235000019804 chlorophyll Nutrition 0.000 title 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 210000004087 cornea Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002428 photodynamic therapy Methods 0.000 title 1
- 210000003786 sclera Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526414P | 2011-08-23 | 2011-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000432A1 true CL2014000432A1 (es) | 2014-11-28 |
Family
ID=46889394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000432A CL2014000432A1 (es) | 2011-08-23 | 2014-02-21 | Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica. |
Country Status (20)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| WO2013009701A2 (en) | 2011-07-08 | 2013-01-17 | The University Of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| EP2830627B1 (en) | 2012-03-29 | 2024-05-01 | Epion Therapeutics, Inc. | Ocular treatment solutions, delivery devices and delivery augmentation methods |
| RU2635185C2 (ru) * | 2013-12-17 | 2017-11-09 | Иван Дмитриевич Захаров | Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости |
| US11207410B2 (en) | 2015-07-21 | 2021-12-28 | Avedro, Inc. | Systems and methods for treatments of an eye with a photosensitizer |
| CN106620893B (zh) * | 2015-07-23 | 2021-07-30 | 爱博诺德(北京)医疗科技股份有限公司 | 用于眼部疾病光治疗的材料 |
| US10449090B2 (en) | 2015-07-31 | 2019-10-22 | Allotex, Inc. | Corneal implant systems and methods |
| CN105601638B (zh) * | 2016-01-28 | 2018-10-26 | 东北林业大学 | 一种叶绿酸衍生物及其制备方法、作为光敏抑菌剂及光敏杀虫剂的应用 |
| US10342697B2 (en) | 2016-04-13 | 2019-07-09 | Avedro, Inc. | Systems and methods for delivering drugs to an eye |
| US20170319329A1 (en) * | 2016-05-05 | 2017-11-09 | David Muller | Corneal Implant Systems and Methods |
| AU2017390276A1 (en) * | 2017-01-03 | 2019-06-27 | Vitrean, Inc. | Methods and devices for treating a retinal detachment |
| JP7364552B2 (ja) * | 2017-08-02 | 2023-10-18 | ザ ユニバーシティ オブ シカゴ | Ｘ線誘起光線力学療法、放射線療法、放射線力学療法、化学療法、免疫療法、及びそれらの任意の組み合わせのための、ナノスケール金属有機層及び金属有機ナノプレート |
| CN109091685A (zh) * | 2018-08-10 | 2018-12-28 | 北京市眼科研究所 | 一种对角膜炎提取细菌病原体的灭活方法 |
| US11702546B2 (en) | 2018-10-24 | 2023-07-18 | California Institute Of Technology | Near-infrared heptamethine dyes for generation of singlet oxygen |
| CN113286788A (zh) * | 2018-10-24 | 2021-08-20 | 加州理工学院 | 使用单线态氧治疗近视和其他眼病症 |
| US20220041563A1 (en) * | 2018-12-04 | 2022-02-10 | Avedro, Inc. | Compounds and Compositions for Eye Treatments |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL102645A (en) | 1992-07-26 | 1998-02-22 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| IL133253A0 (en) * | 1999-12-01 | 2001-04-30 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
| RU2201219C2 (ru) * | 2001-04-24 | 2003-03-27 | Макаров Константин Алексеевич | Фармакологическая композиция пролонгированного действия |
| US20040266748A1 (en) * | 2001-10-03 | 2004-12-30 | Robinson Byron C | Photosensitizing carbamate derivatives |
| IL152900A0 (en) * | 2002-11-17 | 2003-06-24 | Yeda Res & Dev | Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses |
| ES2602460T3 (es) * | 2004-06-07 | 2017-02-21 | Yeda Research And Development Co., Ltd. | Derivados de bacterioclorofila catiónicos y usos de los mismos |
| EP2061512B1 (en) * | 2006-08-23 | 2019-10-02 | Yeda Research And Development Co. Ltd. | Conjugates of rgd peptides and (bacterio)chlorophyll photosensitizers and their uses |
| KR101502632B1 (ko) | 2006-10-24 | 2015-03-17 | 캘리포니아 인스티튜트 오브 테크놀로지 | 신체 조직의 물리적 및/또는 화학적 성질에 영향을 주는 광화학적 요법 |
| RU2404768C1 (ru) * | 2009-10-28 | 2010-11-27 | Федеральное агентство по науке и инновациям | Глазные капли |
| JPWO2011099602A1 (ja) * | 2010-02-12 | 2013-06-17 | 学校法人日本大学 | ポルフィリン誘導体および放射線力学療法におけるその使用 |
-
2012
- 2012-08-23 BR BR112014004306A patent/BR112014004306A2/pt not_active IP Right Cessation
- 2012-08-23 HK HK14113090.6A patent/HK1199412A1/xx unknown
- 2012-08-23 ES ES12762405T patent/ES2856698T3/es active Active
- 2012-08-23 EP EP12762405.4A patent/EP2747763B1/en active Active
- 2012-08-23 US US14/240,328 patent/US9452172B2/en active Active
- 2012-08-23 JP JP2014526601A patent/JP6215203B2/ja active Active
- 2012-08-23 PT PT127624054T patent/PT2747763T/pt unknown
- 2012-08-23 PE PE2014000246A patent/PE20141183A1/es not_active Application Discontinuation
- 2012-08-23 DK DK12762405.4T patent/DK2747763T3/da active
- 2012-08-23 WO PCT/IL2012/050325 patent/WO2013027222A1/en not_active Ceased
- 2012-08-23 RU RU2014110784A patent/RU2632439C2/ru active
- 2012-08-23 KR KR1020147007481A patent/KR101962991B1/ko active Active
- 2012-08-23 CA CA2846011A patent/CA2846011C/en active Active
- 2012-08-23 MX MX2014002107A patent/MX360683B/es active IP Right Grant
- 2012-08-23 CN CN201280045801.9A patent/CN103930108B/zh active Active
- 2012-08-23 IN IN2153CHN2014 patent/IN2014CN02153A/en unknown
- 2012-08-23 HU HUE12762405A patent/HUE053321T2/hu unknown
- 2012-08-23 AU AU2012298156A patent/AU2012298156B2/en not_active Ceased
-
2014
- 2014-02-21 CL CL2014000432A patent/CL2014000432A1/es unknown
- 2014-03-20 ZA ZA2014/02056A patent/ZA201402056B/en unknown
-
2016
- 2016-08-18 US US15/240,221 patent/US20160354468A1/en not_active Abandoned
-
2018
- 2018-11-20 US US16/196,537 patent/US11058772B2/en active Active
-
2021
- 2021-07-08 US US17/370,743 patent/US20210330792A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160354468A1 (en) | 2016-12-08 |
| RU2014110784A (ru) | 2015-09-27 |
| ZA201402056B (en) | 2015-11-25 |
| CA2846011C (en) | 2019-10-15 |
| IN2014CN02153A (cg-RX-API-DMAC7.html) | 2015-05-29 |
| CN103930108B (zh) | 2017-05-24 |
| AU2012298156A1 (en) | 2014-04-10 |
| EP2747763B1 (en) | 2020-12-30 |
| US20210330792A1 (en) | 2021-10-28 |
| EP2747763A1 (en) | 2014-07-02 |
| DK2747763T3 (da) | 2021-03-29 |
| JP2014524465A (ja) | 2014-09-22 |
| MX2014002107A (es) | 2015-04-16 |
| JP6215203B2 (ja) | 2017-10-18 |
| PT2747763T (pt) | 2021-02-22 |
| CA2846011A1 (en) | 2013-02-28 |
| US9452172B2 (en) | 2016-09-27 |
| US20190231874A1 (en) | 2019-08-01 |
| KR101962991B1 (ko) | 2019-03-27 |
| KR20140088514A (ko) | 2014-07-10 |
| AU2012298156B2 (en) | 2017-08-17 |
| BR112014004306A2 (pt) | 2017-03-28 |
| HUE053321T2 (hu) | 2021-06-28 |
| HK1199412A1 (en) | 2015-07-03 |
| MX360683B (es) | 2018-11-13 |
| CN103930108A (zh) | 2014-07-16 |
| ES2856698T3 (es) | 2021-09-28 |
| US11058772B2 (en) | 2021-07-13 |
| PE20141183A1 (es) | 2014-10-05 |
| US20140378888A1 (en) | 2014-12-25 |
| WO2013027222A1 (en) | 2013-02-28 |
| RU2632439C2 (ru) | 2017-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000432A1 (es) | Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica. | |
| IL262591A (en) | Methods for treating patients with familial hypercholesterolemia | |
| EA201991484A1 (ru) | Лекарственные формы энзалутамида | |
| CL2014002549A1 (es) | Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados. | |
| CR20170279A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
| CL2015000061A1 (es) | Anticuerpos biespecíficos anti-vegf/anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares | |
| GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
| EP3473216C0 (en) | DEVICE FOR TREATING AN EYE DISORDER | |
| EA201790575A1 (ru) | Триазолопиразиноны в качестве ингибиторов pde1 | |
| HUE051296T2 (hu) | Benzoxazinon-származékok bõrbetegségek kezelésére | |
| NI201300070A (es) | Ureas asimétricas y usos médicos de las mismas | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| CL2015000926A1 (es) | Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios. | |
| DK3260865T3 (da) | Fremgangsmåde til behandling af blod, blodprodukter og organer | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| ZA201703467B (en) | Methods of treating ocular conditions | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| GB2541840B (en) | Ophthalmic composition for the treatment of ocular infection | |
| MX377506B (es) | Ureas asimetricas p-sustituidas y usos medicos de las mismas. | |
| HUE051295T2 (hu) | Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére | |
| IT201600103956A1 (it) | Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma |